Profile of the Pleximmune blood test for transplant rejection risk prediction

Expert Review of Molecular Diagnostics

Volumn 16, Issue 4, 2016, Pages 387-393

  Sindhi, Rakesh ^a   Ashokkumar, Chethan ^a   Higgs, Brandon W ^a   Levy, Samantha ^b   Soltys, Kyle ^a   Bond, Geoffrey ^a   Mazariegos, George ^a   Ranganathan, Sarangarajan ^c   Zeevi, Adriana ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Plexision Inc   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Acute cellular rejection; CD154; cell based assay; children; flow cytometry; index based; intestine transplantation; Liver transplantation; prognostic; risk of rejection; T cytotoxic memory cells

Indexed keywords

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; CHILD; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VIRUS INFECTION; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL (TOPIC); DIAGNOSTIC KIT; GRAFT REJECTION; IMMUNOASSAY; INTESTINE; MOLECULAR DIAGNOSIS; PROCEDURES; STANDARDS; TRANSPLANTATION; VALIDATION STUDY;

BIOLOGICAL MARKER; CD40 LIGAND; DIAGNOSTIC KIT;

ADOLESCENT; BIOMARKERS; CD40 LIGAND; CHILD; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOASSAY; INTESTINES; LIVER TRANSPLANTATION; MOLECULAR DIAGNOSTIC TECHNIQUES; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 84958531527     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1139455     Document Type: Article

References (32)

1. 2014 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2014 [Internet]. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI [cited 2015 Jul 1]. Available from: https://optn. transplant.hrsa.gov/converge/data/citing.asp
2. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010; 25 (1): 61-74.
3. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transpl. 2008; 8 (2): 396-403.
4. Nayyar N, Mazariegos G, Ranganathan S, et al. Pediatric small bowel transplantation. Semin Pediatr Surg. 2010; 19 (1): 68-77.
5. International Panel, Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997; 25 (3): 658-663.
6. Wu T, Abu-Elmagd K, Bond G, et al. A schema for histologic grading of small intestine allograft acute rejection. Transplantation. 2003; 75 (8): 1241-1248.
7. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg. 2009; 250 (4): 567-581.
8. Al-Awwa IA, Hariharan S, First MR. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis. Am J Kidney Dis. 1998; 31 (6 Suppl 1): 15S-18S.
9. Kaltenborn A, Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transpl. 2013; 8: 685-696.
10. Safa K, Riella LV, Chandraker A. Beyond calcineurin inhibitors: emerging agents in kidney transplantation. Curr Opin Nephrol Hypertens. 2013; 22 (6): 689-697.
11. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant. 2006; 6 (8): 1913-1921.
12. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998; 65 (11): 1481-1489.
13. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant. 2005; 5 (8): 1971-1975.
14. Sindhi R, Ashokkumar C, Higgs BW, et al. Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation. Pediatr Transpl. 2012; 16 (1): 83-91. Erratum in: Pediatr. Transplant. 16 (8), 913 (2012).
15. Ashokkumar C, Talukdar A, Sun Q, et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant. 2009; 9 (1): 179-191.
16. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280 (14): 735-739.
17. Farmer DG, Venick RS, Colangelo J, et al. Pretransplant predictors of survival after intestinal transplantation: analysis of a single-center experience of more than 100 transplants. Transplantation. 2010; 90 (12): 1574-1580.
18. Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation. 2015; 99 (7): 1416-1422.
19. Wozniak LJ, Venick RS, Gordon Burroughs S, et al. Utility of an immune cell function assay to differentiate rejection from infectious enteritis in pediatric intestinal transplant recipients. Clin Transpl. 2014; 28 (2): 229-235.
20. Fang KC. Clinical utilities of peripheral blood gene expression profiling in the management of cardiac transplant patients. J Immunotoxicol. 2007; 4 (3): 209-217.
21. Ashokkumar C, Gupta A, Sun Q, et al. Allospecific CD154+ T cells identify rejection-prone recipients after pediatric small-bowel transplantation. Surgery. 2009; 146 (2): 166-173.
22. Sindhi R, Magill A, Bentlejewski C, et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant. 2005; 5 (1): 96-102.
23. Khera N, Janosky J, Zeevi A, et al. Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci. 2007; 12: 660-663.
24. Ashokkumar C, Shapiro R, Tan H, et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. Transplantation. 2011; 92 (4): 433-438.
25. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant. 2007; 7 (5): 1055-1061.
26. Designating Humanitarian Use Devices. [cited 2015 Jan 23]. A v a i l a b l e f r o m : ht t p ://w w w . f d a . g o v/F o r Indu s t r y/D e v e l o p i n g P r o d u c t s f o r R a r e D i s e a s e s C o n d i t i o n s/DesignatingHumanitarianUseDevicesHUDS/default.htm
27. Eydelman MB, Chen EA. The FDA's humanitarian device exemption program. Health Aff (Millwood). 2011; 30 (6): 1210-1212. author reply (1212).
28. National Committee for Clinical Laboratory Standards (NCCLS). Evaluation of precision performance of quantitative measurement methods; Approved guideline. 2nd ed. Wayne (PA): NCCLS document EP5-A2; 2004.
29. Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting cellular rejection with a cell-based assay: pre-clinical and clinical evaluation in children. Transplantation. In Press.
30. FDA U.S. Food and Drug Administration, Recently-Approved Devices [Internet]. 2014 [cited 2015 Jul 1]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=h130004
31. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012; 18 (11): 1333-1342.
32. Ranganathan S, Celik N, Mazariegos G, et al. Liver allograft fibrosis and minimization of immunosuppression. Pediatr Transpl. 2015; 19 (7): 667-668.